Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response

J Clin Virol. 2003 Jan;26(1):95-100. doi: 10.1016/s1386-6532(02)00044-6.

Abstract

Background: While in the past human cytomegalovirus (HCMV) represented the major viral opportunistic pathogen in patients with AIDS, incidence of HCMV disease in HIV-infected patients drastically dropped after introduction of highly active antiretroviral therapy (HAART). However, cases of HCMV disease in HIV-infected patients treated with HAART have been reported.

Objective: A 38-year-old HIV-infected patient developed HCMV retinitis in May 1999 after reaching a nadir of 69 CD4(+) T cells/microl. HAART and anti-HCMV treatments with parenteral ganciclovir (GCV) were started, resulting in HIV viremia suppression, rise in CD4(+) T cell count to >300 cells/microl and recovery from retinitis. Notwithstanding the apparent immune reconstitution, every attempt to discontinue GCV maintenance treatment was followed by a relapse of retinal lesions. Thus, HCMV-specific CD4(+) cellular immune response was investigated.

Results: Lymphoproliferation assay and cytokine flow cytometry analysis were performed repeatedly from November 1999 showing absolute lack of HCMV specific CD4(+) T cell response, in the presence of an efficient lymphoprolipherative response against another pathogen (Candida) or a mitogen (Phytohemoagglutinin).

Conclusion: In some patients, immune reconstitution after HAART may be only partial, since lack of pathogen-specific CD4(+) T cell response may persist even in the case of a significant rise in the absolute CD4(+) T cell count. This case suggests that immunologic assays investigating specific immune response against HCMV in HIV infected patients may be more useful than the CD4(+) T cell count alone in assessing immune function reconstitution after HAART and in deciding interruption of anti-HCMV secondary prophylaxis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / etiology*
  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active*
  • Antiviral Agents / therapeutic use
  • CD4 Lymphocyte Count*
  • CD4-Positive T-Lymphocytes / immunology*
  • Cytomegalovirus Retinitis / drug therapy
  • Cytomegalovirus Retinitis / etiology*
  • Didanosine / therapeutic use
  • Follow-Up Studies
  • Ganciclovir / therapeutic use
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Lamivudine / therapeutic use
  • Lymphocyte Activation
  • Male
  • Nevirapine / therapeutic use
  • Recurrence
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Stavudine / therapeutic use
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Antiviral Agents
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine
  • Nevirapine
  • Stavudine
  • Didanosine
  • Ganciclovir